(Q44299626)

1 December 2017

title

Sandostatin LAR (long-acting octreotide acetate) for malignant carcinoid syndrome: a 3-year experience (English)

1 reference

1 December 2017

1 reference

Garland J

1

1 reference

1 December 2017

Buscombe JR

2

1 reference

1 December 2017

Bouvier C

3

1 reference

1 December 2017

Bouloux P

4

1 reference

1 December 2017

Chapman MH

5

1 reference

1 December 2017

Chow AC

6

1 reference

1 December 2017

Reynolds N

7

1 reference

1 December 2017

Caplin ME

8

1 reference

1 December 2017

language of work or name

English

0 references

publication date

1 February 2003

1 reference

Alimentary Pharmacology & Therapeutics

1 December 2017

published in

1 reference

1 December 2017

volume

17

1 reference

1 December 2017

issue

3

1 reference

1 December 2017

page(s)

437-444

1 reference

An analysis of 8305 cases of carcinoid tumors

1 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01420.X

Natural history of neuroendocrine enteropancreatic tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01420.X

Comparative studies on the expression of somatostatin receptor subtypes, outcome of octreotide scintigraphy and response to octreotide treatment in patients with carcinoid tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01420.X

Established clinical use of octreotide and lanreotide in oncology

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01420.X

A somatostatin analogue inhibits MAP kinase activation and cell proliferation in human neuroblastoma and in human small cell lung carcinoma cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01420.X

Regression of metastatic carcinoid tumors with octreotide therapy: two case reports and a review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01420.X

NIH conference. Somatostatin and somatostatin analogue (SMS 201-995) in treatment of hormone-secreting tumors of the pituitary and gastrointestinal tract and non-neoplastic diseases of the gut.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01420.X

10.1046/J.1365-2036.2003.01420.X

21 January 2018

Identifiers

DOI

1 reference

1 December 2017

1 reference